E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Epithelial ovarian cancer (EOC) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10033128 |
E.1.2 | Term | Ovarian cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To demonstrate that avelumab in combination with platinum-based chemotherapy followed by avelumab maintenance (Arm C) is superior to platinum-based chemotherapy alone followed by observation (Arm A) in prolonging progression free survival (PFS) in patients with previously untreated epithelial ovarian cancer (EOC).
2. To demonstrate that platinum-based chemotherapy alone followed by avelumab maintenance (Arm B) is superior to platinum-based chemotherapy alone followed by observation (Arm A) in prolonging PFS in patients with previously untreated EOC. |
|
E.2.2 | Secondary objectives of the trial |
• To compare Arm C and Arm B to Arm A in patients with untreated EOC, with respect to overall survival. • To evaluate the anti-tumor activity in each arm. • To evaluate the overall safety profile in each arm. • To evaluate the pharmacokinetics of paclitaxel and carboplatin alone and in combination with avelumab. • To evaluate the PK of avelumab alone and in combination with carboplatin-paclitaxel (Arms B and C). • To evaluate the immunogenicity of avelumab alone and in combination with carboplatinpaclitaxel (Arms B and C). • To evaluate candidate predictive biomarkers of sensitivity or resistance to avelumab in combination with and/or following carboplatin-paclitaxel in pre-treatment tumor tissue, that may aid in the identification of patient subpopulations most likely to benefit from treatment. • To evaluate patient reported outcome in each treatment arm in patients with previously untreated EOC including the assessment of treatment side effects and diseaserelated symptoms. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Histologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer (according to AJCC/UICC TNM and International Federation of Gynecology and Obstetrics (FIGO) Staging System 2014 edition), including malignant mixed Müllerian tumors with high grade serous component. 2. Patients must be candidates for platinum-based chemotherapy and previously untreated. 3. Patients must have completed a surgical debulking procedure, or be candidates for neoadjuvant chemotherapy. a. For patients enrolling after debulking surgery, the following conditions must be met: • The minimum surgery required is an abdominal surgery with an attempt at cytoreduction providing tissue for histologic evaluation and establishing and documenting the primary site and stage. • Patient must be randomized at a maximum of 8 weeks after surgery. b. For patients who are candidates for neoadjuvant chemotherapy, the following conditions must be met: • A core tissue (not fine needle aspiration) biopsy is required. The tissue must be consistent with a tumor of Müllerian origin. • Stage IIIC–IV documented via imaging or surgery (without attempt at cytoreduction). • Serum CA125/ CEA ratio > 25. If the serum CA125/CEA ratio is < 25, workup should be negative for the presence of a primary gastrointestinal or breast malignancy (< 6 weeks before randomization). • Plan to receive carboplatin-paclitaxel neoadjuvant chemotherapy. • Randomization must occur within 8 weeks after diagnosis. 4. Availability of an archival formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 15 slides. If archived FFPE tissue is not available, a de novo (ie, fresh) tumor sample must be obtained in accordance with local institutional practice for tumor biopsies. 5. Eastern Cooperative Group (ECOG) performance status 0-1 6. Age ≥18 years (or ≥20 years in Japan). 7. Adequate hematological function (ANC ≥1.5 x 10 to the power 9/L, Hgb ≥9.0 g/dL, and platelet count ≥100 x 10 to the power 9/L). 8. Adequate liver function tests (ALT/AST ≤2.5 x ULN, total serum bilirubin level ≤1.5 x ULN). 9. Adequate renal function by estimated creatinine clearance ≥50 mL/min as calculated using the Cockcroft-Gault method. 10. Estimated life expectancy of at least 12 weeks. 11. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. 12. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 13. Patients of childbearing potential and at risk for pregnancy must agree to use 2 highly effective methods of contraception throughout the study and for at least 60 days after the last dose of assigned treatment. Patients of non-childbearing potential must meet at least one of the following criteria: • Have undergone a documented hysterectomy and/or bilateral oophorectomy; • Have medically confirmed ovarian failure; or • Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed by having a serum follicle-stimulating hormone (FSH) level confirming the post-menopausal state. All other patients (including patients with tubal ligations) will be considered to be of childbearing potential. |
|
E.4 | Principal exclusion criteria |
1. Non-epithelial tumors, or ovarian tumors with low malignant potential (ie, borderline tumors). 2. Mucinous tumors. 3. Patients for whom, in the opinion of the Investigator, there is clinical benefit to administer bevacizumab as a first-line treatment and for whom bevacizumab is approved and available in this setting. 4. Cancer for which intraperitoneal cytotoxic chemotherapy is planned. 5. Prior systemic anti-cancer treatment for EOC, FTC, or PPC. 6. Prior immunotherapy with IL-2, IFN-α, or anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (anti-CTLA-4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways. 7. Major surgery (other than debulking surgery) for any reason within 4 weeks prior to randomization and/or incomplete recovery from surgery. 8. Known brain, leptomeningeal, or spinal cord metastases. 9. Current or prior use of immunosuppressive medication within 7 days prior to randomization, except the following: intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection); systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or equivalent; steroids as premedication for hypersensitivity reactions [eg, computed tomography (CT) scan premedication]. 10. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agents except patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroidism not requiring immunosuppressive treatment. 11. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, deep vein thrombosis or symptomatic pulmonary embolism. 12. Active and clinically significant bacterial, fungal or viral infection, any positive tests for hepatitis B (HBV), hepatitis C (HCV) indicating acute or chronic infection (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive), known history of a positive test for human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness. 13. Administration of a live vaccine within 30 days prior to study entry. 14. Known severe hypersensitivity reactions to monoclonal antibodies, carboplatin, paclitaxel, or other platinum-containing compounds (NCI CTCAE v4.03 Grade ≥3). 15. Persisting NCI CTCAE v4.03 Grade >1 toxicity related to prior therapy. 16. Previous malignant disease other than the target malignancy to be investigated in this trial within the last 5 years with the exception of adequately treated basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, lobular carcinoma in situ (LCIS), or ductal carcinoma in situ (DCIS). 17. Patients who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees directly involved in the conduct of the study. 18. Participation in other clinical studies involving investigational drug(s) within 4 weeks prior to study randomization and/or during study participation. 19. Other severe/severe acute or chronic medical, including colitis, inflammatory bowel disease, and pneumonitis, or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior) or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. 20. Pregnant patients or breastfeeding patients. 21. Patients with bleeding tumors. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Progression-free survival (PFS) as determined by blinded independent central review (BICR) by RECIST version 1.1 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Efficacy: Overall survival (OS), PFS by Investigator assessment as well as Objective response (OR), Duration of response (DR), Maintenance PFS by BICR assessments and Investigator assessment, pathological Complete Response (pCR), PFS2, and PFS by Gynecological Cancer Intergroup (GCIG) criteria • Safety: AEs (as graded by NCI CTCAE v.4.03); laboratory abnormalities (as graded by NCI CTCAE v.4.03); vital signs (blood pressure, pulse rate); electrocardiograms (ECGs) • Patient-Reported Outcomes: FOSI-18 and EuroQoL5 Dimension (EQ-5D-5L) • Pharmacokinetics: PK parameters, including Ctrough, Cmax, volume of distribution (Vd), clearance (CL), area under the concentration time curve (AUC) for avelumab, paclitaxel, and carboplatin, as data permit • Immunogenicity: anti-drug antibodies (ADA) and neutralizing antibodies (Nab) against avelumab • Candidate predictive biomarkers in tumor tissue including, but not limited to, PD-L1 expression and tumor infiltrating CD8+ T lymphocytes as assessed by immunohistochemistry (IHC) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 84 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Bulgaria |
Canada |
Croatia |
Estonia |
Germany |
Hong Kong |
Hungary |
Ireland |
Italy |
Japan |
Korea, Republic of |
Latvia |
Mexico |
Netherlands |
Poland |
Romania |
Russian Federation |
Singapore |
Slovakia |
Switzerland |
Taiwan |
Turkey |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 11 |